Figure 4.

Changes in transcranial magnetic stimulation (TMS) parameters with Kings clinical stages and disease duration. Short‐interval intracortical inhibition (SICI) was significantly increased at baseline and remained stable across King’s stages but increased with disease duration. Intracortical facilitation (ICF) was increased while cortical silent period (CSP) duration was reduced at baseline and did not change with Kings clinical stages or disease duration. The motor‐evoked potential (MEP) amplitude was increased at baseline and increased with Kings clinical stages and disease duration. The resting motor threshold (RMT) was comparable with controls and did not evolve with Kings clinical stage or disease duration.